SUMMIT trial shows bezuclastinib reduces symptom burden and mast cell markers significantly in non-advanced systemic mastocytosis
SUMMIT trial shows bezuclastinib reduces symptom burden and mast cell markers significantly in non-advanced systemic mastocytosis
In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia …
A new international trial aims to confirm the benefit of adding masitinib to chemotherapy in men with metastatic …
Hope rises for patients with relapsed or refractory acute myeloid leukemia carrying the NPM1 mutation as revumenib moves …
New option opens for patients who have exhausted several therapies in their fight against relapsed or refractory multiple …
Recent clinical developments offer hope for immunosuppression-free diabetes treatment while raising serious questions about safety in gene therapy …
Company Overview and Focus Biodexa Pharmaceuticals PLC, a clinical-stage biotechnology company dedicated to developing innovative treatments for diseases …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Inclusion in major indexes highlights aTyr’s expanding biotech footprint and investor recognition amid advancing therapeutic pipeline.
